Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER2 | P43116 | 7/20 | 0.47 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.47 |
| ▸ | NAMPT | P43490 | 6/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA5A | P35218 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | RORC | P51449 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.33 |
| ▸ | KLK1 | P06870 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL533544 | 0.91 | PTGER2 (0.48) | PTGER2PTGER4NAMPTCA12CA1 | |
| SCHEMBL11026027 | 0.86 | PTGER2 (0.49) | PTGER2PTGER4NAMPTCA12CA1 | |
| SCHEMBL533244 | 0.84 | PTGER2 (0.65) | PTGER2PTGER4 | |
| Hydrochloric Acid SCHEMBL533631 | 0.84 | PTGER2 (0.65) | PTGER2PTGER4 | |
| SCHEMBL533444 | 0.83 | PTGER2 (0.52) | PTGER2PTGER4NAMPTCA12CA1 | |
| SCHEMBL10316685 | 0.82 | PTGER2 (0.46) | PTGER2PTGER4NAMPTMEN1MAPT | |
| SCHEMBL10316684 | 0.81 | PTGER2 (0.72) | PTGER2PTGER4 | |
| SCHEMBL15412004 | 0.81 | PTGER2 (0.48) | PTGER2PTGER4NAMPTCA12CA1 | |
| SCHEMBL533071 | 0.80 | PTGER2 (0.47) | PTGER2PTGER4NAMPTCA12CA1 | |
| SCHEMBL28716177 | 0.79 | PTGER2 (0.49) | PTGER2PTGER4NAMPTCA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120226036-A1 | SUBSTITUTED CARBONYL COMPOUND | UBE INDUSTRIES, LTD. (JP) | 2012-09-06 | — | — | US | claimed |
| US-20120226036-A1 | SUBSTITUTED CARBONYL COMPOUND | UBE INDUSTRIES, LTD. (JP) | 2012-09-06 | — | — | US | disclosed |
| EP-2476678-A1 | SUBSTITUTED CARBONYL COMPOUNDS | Ube Industries, Ltd. (JP) | 2012-07-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120226036-A1 | SUBSTITUTED CARBONYL COMPOUND | PTGER2, PTGER1, LTB4R2 | PTGER2 1/4885PTGER4 10/4885NAMPT 3468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.